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Introduction {#sec005}
============

Oral squamous cell carcinoma (OSCC) is one of the most common types of cancer in the world, with a considerable incidence of new cases every year. Approximately 50% of the patients with OSCC present with early stage disease(cT1-2N0) \[[@pone.0170322.ref001]\]. The main prognostic factor is occult lymph node metastasis in the neck. As it was reported in previous literatures, the overall rate of occult lymph node metastasis is 20%-30% in early stage OSCC patients \[[@pone.0170322.ref002]--[@pone.0170322.ref004]\]. Therefore, elective neck dissection remains the gold standard treatment in many institutions, resulting in overtreatment in over 70% of early OSCC patients and a considerable morbidity. For this reason, in recent years, sentinel lymph node biopsy(SLNB) has become more important and popular in the cervical treatment of patients with early OSCC. The sentinel lymph node (SLN) procedure is based on the theory that flow from a primary tumor travels sequentially to the sentinel lymph node and subsequently to the remaining lymph node basin \[[@pone.0170322.ref005]\]. Compared to elective neck dissection, SLNB is less invasive, cost-effective and beneficial to patient quality of life \[[@pone.0170322.ref006]--[@pone.0170322.ref009]\]. But the diagnostic efficacy of SLNB in early OSCC remains controversial \[[@pone.0170322.ref010]--[@pone.0170322.ref012]\]. Furthermore, most previous individual studies contained too small of a sample size to yield a valid conclusion. In addition, previous meta-analyses mainly focused on head and neck cancer or oral and oropharyngeal carcinoma \[[@pone.0170322.ref013]--[@pone.0170322.ref016]\]. However, combining different subset of head and neck cancer with differing clinical characteristics and metastasis patterns, can lead to heterogeneous results for SLNB. Although some previous meta-analyses have conducted subgroup analysis on OSCC, the small included sample size was underpowered to yield credible pooled findings. In recent years, many high quality prospective and some multi-institutional studies on the diagnostic efficacy of SLNB in early OSCC have been published \[[@pone.0170322.ref017]--[@pone.0170322.ref019]\]. Therefore, we performed a meta-analysis to summarize the diagnostic efficacy of SLNB specially focused exclusively on early OSCC. Additionally, we further stratified results by different clinical and study characteristics in order to explore the potential factors that may affect the diagnostic accuracy and applicability of SLNB.

Materials and Methods {#sec006}
=====================

Search strategy {#sec007}
---------------

We conducted a search for relevant literatures published up to September 11, 2016 in PubMed, Embase, Web of Science and Cochrane Library. The following medical subject headings(MeSH) and keywords were used: (\"oral neoplasm\" or \"oral cancer\" or \"oral tumor\" or \"mouth neoplasm\" or \"mouth cancer\" or \"mouth tumor\" or \"head and neck neoplasm\" or \"head and neck cancer\" or \"head and neck tumor\") and (\"sentinel lymph node biopsy\" or \"sentinel\"). We used no language restrictions. We also manually searched the reference lists of eligible studies and ClinicalTrials.gov to ensure identification of relevant published and unpublished studies.

Inclusion and exclusion criteria {#sec008}
--------------------------------

Articles included need to fulfill the following criteria: (1) Human cT1/T2N0 oral cavity squamous cell carcinoma patients (in studies that included T3, T4, N+ or other head and neck tumor cases, only the cT1--T2N0 oral cancer cases were selected); (2) the use of radioactive tracer, blue dye or indocyanine green; (3) presence of \"gold standard\", which was defined as the use of histological evaluation and follow-up; (4) studies presented sufficient data to allow for the construction of 2×2 tables, including true positive (TP), false positive (FP), false negative (FN) and true negative (TN); (5) Full text available in English. Studies that met the following criteria were excluded: (1) reports of duplicate data published in other studies; (2) letters, editorials, case reports or reviews; (3) studies without qualified data; (4) studies that included T3, T4 or N^+^ oral cavity cases or other head and neck tumors and not possible to be separated; (5) Full text in English unavailable.

Two reviewers(MY Liu and XH Yang) independently performed first-stage screening of titles and abstracts based on the research question. For the second screening, we retrieved articles in full text according to the initial screening. Any discrepancies were resolved by discussion or referred to a third author.

Data extraction and quality assessment {#sec009}
--------------------------------------

Two investigators (MY Liu and XH Yang) independently reviewed the full texts of included studies and recorded the following data: first author, year of publication, sample size, description of study population (age), study design (prospective or retrospective), pathology (H&E staining, immunohistochemistry (IHC), serial sectioning (SS)), SLN tracer, SLN identification rate, average of SLNs harvested, data for diagnostic meta-analysis (TP, FP, FN, and TN) and so on. Results were then compared and any disagreements were settled by consensus. Concerning the quality of study design, study quality was assessed with the QUADAS-2 checklist for studies of diagnostic accuracy included in systematic reviews \[[@pone.0170322.ref020]\].

Analysis {#sec010}
--------

The identification rate, sensitivity and negative predictive value together with their 95% confidence intervals (95% CIs) were summarized in the current meta-analysis. The sensitivity and specificity of each included study were used to plot the summary receiver operator characteristic (SROC) curve and calculate the area under the SROC curve (AUC).

Q tests and *I*^2^ statistics were used to assess the degree of heterogeneity between studies. A *p* value less than 0.1 for the Q test and an *I*^2^ higher than 50% indicated the existence of significant heterogeneity. Pooled estimates were derived using the fixed-effects model if significant heterogeneity was not present. In case of heterogeneity, the random-effects model was applied.

We assessed diagnostic threshold effect with use of the spearman correlation coefficient. In addition, We further stratified results by the average of SLNs harvested (low: \<2, medium: 2≤ and \<3 or high: ≥3), SLN pathology methods(IHC or not, SS or not), type of reference test(neck dissection or follow-up), SLN tracer(single tracer or multiple tracers), study design (prospective or retrospective) and publication year(early: 2000--2008 or late: 2009--2016) in view of the greater effect of different study characteristics on diagnostic efficacy of SLN, and to explore the sources of between-study heterogeneity.

In this meta analysis, we performed a sensitivity analysis to evaluate the credibility and consistency of the results through omitting studies one by one and comparing the pooled results of random-effects model and fixed-effects model. Publication bias was assessed by using Deeks\' funnel plot.

Two-sided *p* values were calculated with *p*\<0.05 considered significant for all tests. We did statistical analysis with Review Manager (version 5.3.5), Meta-DiSc (version 1.4), Comprehensive Meta Analysis (version 2.0) and STATA (version 12).

Results {#sec011}
=======

Search results and study selection {#sec012}
----------------------------------

[Fig 1](#pone.0170322.g001){ref-type="fig"} shows the study flowchart. The initial search returned a total of 3183 studies, of which 1177 were excluded as duplications. The remaining 2006 articles were subject to further evaluation. After titles and abstracts were reviewed, 1829 were excluded, leaving 177 articles available for full text review. After full text review, an additional 111 manuscripts were excluded (the reasons were presented on [Fig 1](#pone.0170322.g001){ref-type="fig"}). Finally, 66 studies fulfilled the inclusion criteria for the meta analysis, comprising 3566 patients \[[@pone.0170322.ref005], [@pone.0170322.ref010]--[@pone.0170322.ref012], [@pone.0170322.ref017]--[@pone.0170322.ref019], [@pone.0170322.ref021]--[@pone.0170322.ref079]\] ([Fig 1](#pone.0170322.g001){ref-type="fig"}).

![Study flow diagram.](pone.0170322.g001){#pone.0170322.g001}

Study characteristics {#sec013}
---------------------

[Table 1](#pone.0170322.t001){ref-type="table"} summarizes individual studies and their characteristics. Of the 66 studies, the publication years of the included articles ranged from 2000 to2016 (26 articles were published during 2000 and 2008 while 40 articles were published during 2009 and 2016). Among the 66 studies, 56 researches were prospective while 10 studies were retrospective. Additionally, 43 studies detected the SLN by single tracer while 23 studies by multiple tracers. In all included studies, SLN was diagnosed based on histopathology(H&E staining, IHC and/or SS), which is considered the gold standard reference for SLN metastasis diagnosis. Of the total 3566 cases, SLN could be harvested in 3516 cases. The pooled SLN identification rate was 96.3%(95% CI: 95.3%-97.0%). The data of average SLN harvested per person was reported in 38 studies. The TP, FP, FN and TN results for individual studies were shown in [Table 1](#pone.0170322.t001){ref-type="table"}.

10.1371/journal.pone.0170322.t001

###### Basic characteristics of included studies.

![](pone.0170322.t001){#pone.0170322.t001g}

  study         year   Design   Population   Index Test         Reference Test ND or FU(mean, range)   Outcome                                                                                    
  ------------- ------ -------- ------------ ------------------ -------------------------------------- ------------------ --------- ----------------------------- --------- ------ ----- --- ---- -----
  Ramamurthy    2014   Pros     32           43(26--70)         B                                      B                  H+I+S     ND                            29/32     1.56   4     0   1    24
  Chung         2015   Pros     61           49.3(10.3)         R                                      L+G                H+I+S     FU (70months, 49--111)        61/61     NR     12    0   5    44
  Julio         2007   Pros     14           65.9(13.7)         R+ICG                                  L+G                H+I       ND                            14/14     3.2    3     0   0    11
  Heuveling     2014   Pros     66           NR                 R+B                                    L+G+B+SPECT        Unclear   ND                            66/66     2      11    0   2    53
  Terada        2011   Pros     45           62(30--85)         R                                      L+G+SPECT          H         FU (46months, 9--72)          45/45     NR     5     0   5    35
  Barzan        2002   Pros     10           64(36--85)         R                                      G                  Unclear   ND                            9/10      NR     2     0   0    7
  Bluemel       2014   Pros     23           58.7(13)           R                                      L+G+SPECT/CT       H+I+S     ND                            23/23     3.1    5     0   0    18
  Terada        2008   Pros     43           NR                 R                                      L+G+SPECT/CT       Unclear   ND                            41/43     NR     5     0   1    35
  Chiesa        2000   Pros     11           NR                 R                                      L+G                Unclear   ND                            10/11     NR     3     0   0    7
  Dequanter     2013   Pros     20           64(?)              R                                      L+G                H+I+S     FU (59months, ?-?)            20/20     NR     4     0   0    16
  Broglie       2011   Pros     69           60(?)              R                                      L+G+SPECT+PET-CT   Unclear   FU (59.8months, 2.6--120.7)   69/69     NR     23    0   2    44
  Vigili        2007   Pros     12           57.4(?)            R                                      L+G                H+I       ND                            12/12     2.1    5     0   0    7
  Aida          2014   Pros     25           61.2(42--82)       R                                      L+G+SPECT/CT       Unclear   FU (?months, 7--88)           25/25     NR     8     0   0    17
  Joost         2013   Pros     7            59.5(33--73)       ICG                                    NI                 H         ND                            7/7       1.7    2     0   1    4
  Bilde         2008   Pros     51           58(29--90)         R                                      L+G+SPECT/CT       H+I+S     ND                            51/51     3      11    0   0    40
  Chaturvedi    2015   Pros     53           44(29--70)         R                                      L+G+SPECT          H         ND                            51/53     3.8    10    0   4    37
  Yen           2006   Pros     25           47.8(30--66)       R                                      L+G                H+I+S     ND                            24/25     2.4    6     0   0    18
  Minamikawa    2005   Retro    18           NR                 B                                      B                  Unclear   FU (NR)                       15/18     NR     4     0   1    10
  Ram           2015   Retro    42           61.3(40--83)       R                                      L+G+SPECT/CT       H+I+S     FU (NR)                       42/42     NR     8     0   2    32
  Schilling     2015   Pros     415          61(28--92)         R+B                                    L+G+B              H+I+S     FU (\>36months)               415/415   3.2    94    0   15   306
  Civantos      2010   Pros     140          58(24--90)         R                                      L+G                H+I       ND                            140/140   3      37    0   4    99
  Rigual        2013   Retro    38           62(14)             R                                      L+G                H         FU (31months, 3--71)          38/38     2      5     0   2    31
  Tartaglione   2016   Pros     434          NR                 R+B                                    L+G+B+SPECT/CT     H+I+S     ND                            434/434   3.2    105   0   14   315
  Harri         2008   Pros     13           65(30--84)         R+B                                    L+G+B              H+I+S     FU (21months, 12--42)         13/13     3.1    2     0   0    11
  Pezier        2012   Pros     59           62.5(38--90)       R+B                                    L+G+B              H+I       FU (22.5months, 0.26--53)     57/59     2.6    17    0   1    39
  Hart          2005   Pros     12           62.75(35--83)      R                                      L+G                H+I+S     ND                            12/12     NR     2     0   0    10
  Keyvan        2016   Pros     10           52(21--82)         R                                      L+G                Unclear   ND                            10/10     2.4    3     0   0    7
  Flach         2014   Pros     62           61.2(28.8--82.6)   R+B                                    L+G+B              H+I+S     FU (52.5months, 5.3--76.7)    62/62     NR     20    0   5    37
  Vishno        2015   Pros     65           47(20--77)         B                                      B                  H+I       ND                            60/65     2.02   7     0   1    52
  Hasegawa      2011   Pros     61           NR                 R                                      G                  Unclear   FU (NR)                       60/61     NR     10    0   3    47
  Burns         2009   Pros     9            59.2(38--80)       R+B                                    L+G+B              H+I       FU (?months, 9--24)           9/9       1.3    3     0   0    6
  Kontio        2004   Pros     15           63.8(35--81)       R+B                                    L+G+B              H+I       ND                            15/15     2.8    3     0   0    12
  Frerich       2007   Pros     26           NR                 R                                      G                  H+I+S     FU (27.5months, 7.2--49.5)    26/26     2.1    8     0   2    16
  Hiraki        2016   Retro    47           65.4(12.6)         R                                      L+G+SPECT/CT       H+S       FU (38.5months, 12.4--64.6)   47/47     2.1    9     0   2    36
  Honda         2015   Pros     31           64(33--91)         B                                      B+CT(Iopamidol)    Unclear   FU (\>30months)               28/31     NR     4     0   1    23
  Fan           2014   Retro    30           48(27--75)         R+B                                    L+G+B              H         FU (\>120months)              30/30     NR     9     0   1    20
  Rigual        2005   Pros     20           NR                 R+B                                    L+G+B              H         ND                            20/20     NR     10    0   2    8
  Stoeckli      2001   Pros     15           56(36--81)         R+B                                    L+G+B              H+I+S     ND                            15/15     NR     3     0   0    12
  Terada        2006   Pros     20           NR                 R                                      L+G+SPECT/CT       H         FU(NR)                        20/20     3.3    6     0   0    14
  Jeong         2006   Pros     20           53(35--68)         R                                      L+G                H+I+S     ND                            20/20     2.55   6     0   0    14
  Thomsen       2007   Pros     39           ?(32--90)          R+B                                    L+G+B              H+I+S     FU (28months, 4--54)          37/39     NR     11    0   0    26
  Hoft          2004   Pros     20           NR                 R                                      L+G                H+I+S     ND                            20/20     3.2    6     0   0    14
  Samant        2014   Pros     34           61(24--82)         R+B                                    L+G+B              H+I       FU(36months, 2--60)           32/34     NR     6     0   2    24
  Toom          2015   Retro    90           60(29--86)         R+B                                    L+G+B+SPECT/CT     H+I+S     FU(18months, 2--62)           87/90     2      26    0   2    59
  Yoshimoto     2012   Retro    145          63(21--92)         R                                      L+G+SPECT/CT       H+I       FU (NR)                       145/145   2.9    24    0   7    114
  Stoeckli      2007   Pros     79           58.5(34--87)       R                                      L+G                H+I+S     FU (19months, 3--40)          78/79     NR     29    0   2    47
  Melkane       2012   Pros     174          56(28--86)         R                                      L+G                H+I+S     FU (\>36months)               166/174   2      42    0   6    118
  Civantos      2003   Pros     14           62(34--79)         R                                      L+G+PET maping     H+I       ND                            14/14     NR     6     0   1    7
  Alvarez       2014   Pros     28           61.2(41--87)       R+B                                    L+G+B              H+I+S     FU (\>60months)               28/28     NR     7     0   4    17
  Peng          2015   Pros     19           60.5(43--77)       B+ICG                                  B+NI               H         ND                            19/19     3.4    3     0   0    16
  Hernando      2016   Pros     32           66.4(40--90)       R                                      L+G                H+I+S     FU (48.2months, 7--70)        32/32     2      3     0   3    26
  Ikram         2013   Pros     42           52(31--75)         R                                      L+G                H+I+S     ND                            38/42     NR     7     0   0    31
  Taylor        2001   Pros     8            61.9(22--80)       R                                      L+G                Unclear   ND                            8/8       NR     3     0   0    5
  Yamauchi      2012   Pros     11           62.3(36--84)       R                                      L+G                H+S       FU (37.1months, 20.1--54.1)   11/11     NR     2     0   1    8
  Thomsen       2005   Pros     40           ?(32--90)          R+B                                    L+G+B              H+I+S     FU (15.8months, 4.3--40.4)    40/40     NR     11    0   3    26
  Pedersen      2016   Retro    253          63(30--95)         R                                      L+G+SPECT/CT       H+I+S     FU (32months, 1--92)          253/253   3      68    0   9    176
  Kaya          2015   Pros     18           54.5(28--76)       R                                      L+G                H+I       ND                            18/18     NR     5     0   0    13
  Tartaglione   2008   Pros     22           62.6(28--80)       R                                      L+G                H+I       FU (23.2months, 10--35)       22/22     2.2    8     0   0    14
  Hernandez     2005   Pros     48           57(28--83)         R+B                                    L+G+B              H+S       ND                            48/48     2      10    0   3    35
  Bilde         2006   Pros     34           58(47--70)         R                                      L+G+SPECT/CT       H+I+S     ND                            32/34     3      6     0   0    26
  Bell          2013   Pros     36           60.5(20--87)       R                                      L+G                H+I+S     ND                            35/36     1.9    7     0   1    27
  Matsuzuka     2014   Retro    29           66(31--82)         R                                      L+G                H         FU (91months, 10--165)        29/29     3.1    6     0   2    21
  Heuveling     2012   Retro    60           60(29--81)         R+B                                    L+G+B              H+I+S     FU (19months, 5--51)          60/60     3      21    0   1    38
  Agrawal       2015   Pros     66           60.8(12.8)         R                                      L+G+SPECT/CT       H+I       ND                            65/66     3.9    30    0   1    34
  Nakamura      2015   Pros     15           63.1(44--84)       R+ICG                                  L+G+NI             Unclear   FU (38.5months, 10.7--69.9)   15/15     2.2    1     0   1    13
  Mozzillo      2001   Pros     41           NR                 R+B                                    L+G+B              Unclear   ND                            39/41     NR     4     0   0    35

Abbreviations: Pros, Prospective; Retro, Retrospective; NR, Not reported; R, Radionucleotide; B, Blue dye; ICG, Indocyanine green; NI, near-infrared fluorescence camera; H, Hematoxylin and eosin; I, Immunohistochemistry; S, Serial sectioning; ND, Neck dissection; FU, Follow-up; SLN, Sentinel lymph node; TP, Ture positive; FP, False positive; FN, False Negative; TN, Ture negative.

Quality of included studies {#sec014}
---------------------------

Quality assessments are shown in a bar graph of QUADAS-2 in [Fig 2](#pone.0170322.g002){ref-type="fig"}. The graph indicates that all included studies were of moderately high quality. Risk of bias regarding patient selection was high in 14 (21.2%) studies mostly due to their retrospective nature without a consecutive or random sample enrollment of patients. Risk of bias regarding index test was unclear in only 1(1.5%) study while 65 (98.5%) studies were low risk. By contrast, the reference standard was unclear in 39 (59.1%) studies because in most of these studies it was unclear whether the index test and reference test were interpreted independently and blindly from each other. For risk of bias in flow and timing there were 23 (34.8%) studies considered high risk mainly due having a the different reference standard. In these studies, patients with positive SLN would undergo a comprehensive neck dissection and pathology results of cervical lymph nodes were the \"gold standard\" however SLN-negative patients would not undergo neck dissection and clinical follow-up was the \"gold standard\". There was less concern about the applicability of the studies. In 5 (7.6%) studies, there were concerns about applicability because of patient selection, in 3 (4.5%) studies because of the index test and in1 (1.5%) study because of the reference test.

![Results of QUADAS-2, Risk of bias and concerns regarding applicability.](pone.0170322.g002){#pone.0170322.g002}

Diagnostic accuracy {#sec015}
-------------------

Analysis of diagnostic threshold showed that the spearman correlation coefficient was -0.037 with a *p*-value of 0.769. Forest plots of data from the 66 studies on the sensitivity and negative predictive value of SLNB are shown in Figs [3](#pone.0170322.g003){ref-type="fig"} and [4](#pone.0170322.g004){ref-type="fig"}, respectively. Since no significant heterogeneity were found between studies in sensitivity and negative predictive value data (*I*^2^ = 20.5% and *I*^2^ = 0.0, respectively), the fixed effects model was used to calculate the pool estimates in this study. In the present analysis, the pooled SLN identification rate, pooled sensitivity and negative predictive value were 96.3%(95% CI: 95.3%-97.0%), 0.87 (95% CI: 0.85--0.89) and 0.94 (95% CI: 0.93--0.95), respectively. [Fig 5](#pone.0170322.g005){ref-type="fig"} shows the corresponding overall SROC curve with an AUC of 0.98 (95% CI: 0.97--0.99). In order to view the greater effect of different study characteristics on the diagnostic efficacy of SLN, subgroup analysis was conducted.

![Forest plot of pooled sensitivity.](pone.0170322.g003){#pone.0170322.g003}

![Forest plot of pooled negative predictive value.](pone.0170322.g004){#pone.0170322.g004}

![SROC curve.](pone.0170322.g005){#pone.0170322.g005}

Subgroup analysis {#sec016}
-----------------

We conducted subgroup analysis by the average of SLNs harvested (low: \<2, medium: 2≤ and \<3 or high: ≥3), SLN pathology methods(IHC or not, SS or not), type of reference test (neck dissection or follow-up), SLN tracer (single tracer or multiple tracers), study design (prospective or retrospective) and publication year (early: 2000--2008 or late: 2009--2016). The pooled sensitivity, negative predictive value and AUC for each subgroup are listed in [Table 2](#pone.0170322.t002){ref-type="table"}.

10.1371/journal.pone.0170322.t002

###### Summary of subgroup analysis by different clinical characteristics.

![](pone.0170322.t002){#pone.0170322.t002g}

  Subgroup             Study (n)   Sensitivity \[95% CIs\]   NPV \[95% CIs\]      AUC \[95% CIs\]
  -------------------- ----------- ------------------------- -------------------- --------------------
  IHC                                                                             
   No                  12          0.77 \[0.68--0.85\]       0.91\[0.87--0.94\]   0.97\[0.95--0.99\]
   Yes                 41          0.88 \[0.86--0.90\]       0.95\[0.94--0.96\]   0.98\[0.97--0.99\]
  SS                                                                              
   No                  21          0.88\[0.84--0.91\]        0.93\[0.91--0.95\]   0.96\[0.93--0.99\]
   Yes                 32          0.87\[0.84--0.90\]        0.94\[0.93--0.95\]   0.98\[0.97--0.99\]
  Average SLNs                                                                    
   Low (N\<2)          4           0.84 \[0.60--0.97\]       0.94\[0.83--0.98\]   0.90\[0.75--1.00\]
   Medium(2≤N\<3)      18          0.86 \[0.81--0.90\]       0.95\[0.93--0.96\]   0.98\[0.97--1.00\]
   High(N≥3)           16          0.88 \[0.86--0.92\]       0.95\[0.94--0.97\]   0.98\[0.97--0.99\]
  Publication Year                                                                
   Early(2000--2008)   26          0.92 \[0.87--0.95\]       0.94\[0.91--0.96\]   0.98\[0.97--0.99\]
   Late(2009--2016)    40          0.86 \[0.83--0.88\]       0.94\[0.93--0.95\]   0.98\[0.96--0.99\]
  SLN Tracer                                                                      
   Single              43          0.87 \[0.84--0.90\]       0.94\[0.93--0.95\]   0.98\[0.97--0.99\]
   Multiple            23          0.87 \[0.84--0.90\]       0.94\[0.93--0.96\]   0.96\[0.93--0.99\]
  Study Design                                                                    
   Prospective         56          0.87 \[0.85--0.90\]       0.94\[0.93--0.95\]   0.98\[0.97--0.99\]
   Retrospective       10          0.86 \[0.81--0.91\]       0.95\[0.93--0.96\]   0.97\[0.92--1.00\]
  Reference Test                                                                  
   ND                  32          0.90 \[0.87--0.93\]       0.95\[0.94--0.96\]   0.97\[0.95--0.98\]
   FU                  34          0.85 \[0.82--0.88\]       0.94\[0.92--0.95\]   0.98\[0.97--0.99\]

ND: neck dissection; FU: follow-up; IHC: immunohistochemistry; SS: Serial sectioning; NPV: negative predictive value.

For subgroup analyses conducted by the average of SLNs harvested, SLN tracer, study design and serial sectioning, no significant difference could be found among these groups. However, subgroup analysis based on immunohistochemistry(IHC) indicated that H&E combined with IHC was significantly more sensitive than single H&E staining with a sensitivity of 0.88(95%CI: 0.86--0.90) versus 0.77(95%CI: 0.68--0.85). Moreover, early publication subgroup and neck dissection subgroup yielded a better pooled sensitivity than late publication subgroup and clinical follow-up subgroup(0.92\[0.87--0.95\] *vs*. 0.86\[0.83--0.88\] and 0.90\[0.87--0.93\] *vs*. 0.85\[0.82--0.88\], respectively).

Sensitivity analysis and publication bias {#sec017}
-----------------------------------------

We performed sensitivity analyses to assess the credibility and consistency of the results through: (1)Omitting studies one by one. In the current meta analysis, with removal of any single study the pooled findings were essentially unchanged. (2) When switched the fixed-effects model to random-effects model, the pooled findings didn\'t change significantly. The sensitivity analyses supported the result was robustness.

In order to evaluate potential publication bias, the Deeks\' funnel plot asymmetry test was used. The slope coefficient was associated with a *P* value of 0.00 ([Fig 6](#pone.0170322.g006){ref-type="fig"}), revealed a likelihood of publication bias.

![Deeks\' funnel plot with regression line.](pone.0170322.g006){#pone.0170322.g006}

Discussion {#sec018}
==========

To our knowledge, this is the largest meta-analysis focused on the diagnostic efficacy of sentinel lymph node biopsy in early oral squamous cell carcinoma. In this meta-analysis of 66 studies comprising more than 3500 patients, SLNB yielded a pooled identification rate of 96.3%(95% CI: 95.3%-97.0%), a pooled sensitivity of 0.87(95%CI: 0.85--0.89), a pooled negative predictive value of 0.94 (95% CI: 0.93--0.95) and an AUC of 0.98 (95% CI: 0.97--0.99). The high pooled negative predictive value implied that only 6% of SLN-negative early oral cavity cancer patients would result in a false-negative regional recurrence during follow-up. This is similar to the regional recurrence rate after elective neck dissection in clinically neck-negative early OSCC reported by previous literature \[[@pone.0170322.ref080]\], and is far lower than the acceptable threshold of 20% cervical lymph node metastasis rate for prophylactic neck dissection. Therefore, elective neck dissection could be omitted in SLN-negative early OSCC patients. Moreover, the pooled sensitivity implies that 87% of occult cervical lymph node metastases could be diagnosed by SLNB and the false-negative rate is 13%. The occult lymph node metastasis rate has been reported to be 20%-30% for cT1-2N0 OSCC \[[@pone.0170322.ref002]--[@pone.0170322.ref004]\]. Therefore, we can estimate that SLNB applied to all early OSCC patients would result in a 2.6%-3.9% regional recurrence rate. This regional recurrence rate is acceptable when considering the serious complications and 70% overtreatment rate in traditional prophylactic neck dissection procedure. Overall, these pooled findings indicated that SLNB had an ideal diagnostic accuracy for predicting occult cervical lymph node metastases in early oral cancer patients and was an ideal alternative to neck dissection. In the previous meta-analyses focusing on the diagnostic efficacy of SLNB in head and neck cancer or oral/oropharyngeal cancer, Tim reported a pooled sensitivity of 0.92 (95%CI: 0.86--0.95) in oral cancer subgroup(n = 508), while Thompson reported a pooled sensitivity and negative predictive value of 0.94 (95%CI: 0.89--0.98) and 0.96 (95%CI: 0.93--0.99) respectively in the subset of oral cavity tumors(n = 631) \[[@pone.0170322.ref014], [@pone.0170322.ref015]\]. Compared to these previous meta-analyses, our research found a lower sensitivity of 0.87(95%CI: 0.85--0.89)(n = 3506). Since those two meta-analyses were published many years ago, we further stratified our results by publication year and found that the pooled sensitivity of early publications(2000--2008) in current meta-analysis was 0.92(95%CI: 0.87--0.95), more similar to the results reported by previous meta-analyses, and better than late publications(2009--2016). A possible reason for this difference may be that SLNB researches in early publications were still during the validation stage, and elective neck dissection of levels I-III was the gold standard for SLN-negative cases in most of these publications(69.2%, 18/26). But in more recent publications, most SLNB research studies use clinical follow-up as their gold standard for SLN-negative cases and only 35%(14/40) of studies were still using elective neck dissection(levels I-III) as their gold standard. Thus, we speculate that: (1) there may have occult lymph node metastases in level IV, level V or even contralateral neck that would be missed by the elective neck dissections in most of the earlier publications, resulting in an overestimated sensitivity; (2) SLNB with neck dissection is definitely easier than SLNB without neck dissection and this may also lead to a higher pooled sensitivity in the validation stage.

Based on our subgroup analyses, we found that SLNB with IHC yielded significantly better sensitivity than the no IHC subgroup. The pooled sensitivity was 0.88(95%CI: 0.86--0.90) in IHC subgroup but only 0.77(95%CI: 0.68--0.85) in the no IHC subgroup. These results indicated that application of IHC associated with a 11% relative increase in sensitivity. Based on this result, we strongly recommend that IHC should be performed for SLN pathologic analysis. By contrast, no significant difference could be found between serial sectioning subgroup and no serial sectioning subgroup. The pooled sensitivity was 0.88(95%CI: 0.84--0.91) and 0.87(95%CI: 0.84--0.90), respectively. A prospective study conducted by Bell demonstrated that SLNB performed with the use of routine H&E staining and IHC could accurately predict neck stage in early oral squamous cell carcinoma with a negative predictive value of 96% and that serial sectioning might not be necessary \[[@pone.0170322.ref075]\]. Meanwhile, routine serial sectioning was also deemed not feasible or practical to make a quick diagnosis for SLN during frozen section. In the current meta-analysis, our results confirmed Bell\'s conclusion.

Several limitations should be considered while interpreting our results. First, although we tried to incorporate all relevant studies, the Deeks\' funnel plot still revealed a likelihood of publication bias. It is possible that we may have missed some eligible studies in our screening process. There may also have been small trials with opposite results that were never published. Second, quality assessment showed that there was high risk of bias in flow and timing because not all patients received the same reference standard. This bias might restrict interpretation of the true diagnostic efficacy of SLNB. Third, in almost all of the included studies, the SLNs were assessed by postoperative pathological procedure but not by frozen section. This might result in overestimating the practical clinical applicability of SLNB. Nevertheless, this didn\'t affect the validity of our pooled findings. Finally, similar to other meta-analyses, we included studies with different characteristics and designs. Nevertheless, the heterogeneity test and sensitivity analyses proved our pooled findings to be credible and consistent. Notwithstanding the limitations listed above, our meta-analysis also has its strengths: (1) this is the largest meta-analysis of the diagnostic efficacy of SLNB specifically focused on early oral squamous cell carcinoma; (2) by dividing studies into two subgroups based on the use of IHC, we confirmed that SLN assessment with IHC achieved a significantly higher sensitivity than without IHC; (3) Moreover, serial sectioning does not seem necessary for SLN assessment.

Conclusions {#sec019}
===========

Our results confirmed that SLNB had a high diagnostic accuracy in cT1-2N0 oral squamous cell carcinoma, and was an ideal alternative to elective neck dissection. We also found that H&E with IHC yielded much better diagnostic sensitivity than H&E alone. However, further clinical trials are required to verify the clinical utility and application of SLNB by frozen section but not by postoperative pathological assessment. In particular, further studies on the diagnostic accuracy of automated quantitative real-time PCR (qRT-PCR) assay for intra-operative SLN frozen section are required \[[@pone.0170322.ref081], [@pone.0170322.ref082]\].

Supporting Information {#sec020}
======================

###### Search Strategy.

(DOCX)

###### 

Click here for additional data file.

###### Methodological Quality Summary.

(TIF)

###### 

Click here for additional data file.

###### PRISMA 2009 Checklist.

(DOC)

###### 

Click here for additional data file.

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.

[^2]: **Conceptualization:** MYL SJW HWP.**Data curation:** MYL SJW YXH.**Formal analysis:** MYL SJW YXH.**Investigation:** MYL SJW YXH.**Methodology:** MYL SJW HWP.**Project administration:** HWP.**Supervision:** HWP.**Visualization:** MYL SJW.**Writing -- original draft:** MYL.**Writing -- review & editing:** SJW HWP.
